PSMA-targeted radioligands, when paired with alpha- or beta-emitting radionuclides, have shown promise in the treatment of advanced metastatic prostate cancer (25), suggesting that similar therapies could be beneficial for brain metastases, which are often associated with neovascularization and PSMA overexpression. Here, FOLH1 is linked to metastatic prostate carcinoma.